blog.aids.gov − Treatment
AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV - Changing to HIV.gov in Spring 2017

MENU

Treatment

AIDSinfo Adds Investigational Therapeutic HIV Vaccine Information to Website

“What is PRO-140?” “In what phase of study is injectable cabotegravir?” “How do latency-reversing agents work?” Answers to all of these questions can be found in the AIDSinfo Drug Database. The database is a federal resource that includes information on both FDA-approved and investigational HIV-related drugs. Information on more than 50 investigational drugs is available…

HRSA Funds New Hepatitis C and HIV Coinfection Initiative

Summary: HRSA’s HIV/AIDS Bureau has awarded a new initiative to improve hepatitis C virus (HCV) services among HIV/HCV coinfected people of color, funded under the FY 2016 Secretary’s Minority AIDS Initiative Fund. HRSA’s HIV/AIDS Bureau has awarded a new initiative to improve hepatitis C virus (HCV) services among HIV/HCV coinfected people of color, funded under…

Back To The Future?

I’m always a bit of a basket case when World AIDS Day comes around each year. The day, which usually stretches into a week’s worth of events for me, stirs up a complex set of emotions in me. The memories of what it was like being diagnosed with HIV on World AIDS Day in 1994….

Large Increases in HIV Suppression Needed to Reduce New Infections in Critical Population

NIH-Funded Study Aims to Identify and Treat HIV-Infected Men Who Have Sex With Men Achieving moderate reduction of new HIV infections among men who have sex with men (MSM) will depend on significantly increasing the percentage of HIV-infected MSM whose viral load is suppressed to undetectable levels, according to a new mathematical model based on…

Final USCA 2016 Facebook Live Events Focus on Viral Suppression and Conference Highlights

On the closing day of the 2016 U.S. Conference on AIDS (USCA), September 18, in Hollywood, Florida, AIDS.gov shared more conference highlights via two Facebook Live events. People Living with HIV Discussed What New Science on Viral Suppression Means to Them Dr. Rich Wolitski held a conversation with four other people living with HIV about…

NIH’s Dr. Carl Dieffenbach Discusses HIV Treatment Science at 2016 Ryan White Conference

As the 2016 National Ryan White Conference on HIV Care and Treatment wound down in Washington, DC, NIH’s Dr. Carl Dieffenbach and his colleague Anne Rancourt joined us for a conversation on Facebook Live about HIV treatment. They discussed what scientists now know about the benefits of HIV treatment and when people diagnosed with HIV…

Updated: Common Patient Assistance Program Application Reduces Barriers to HIV Medication Access

This month, the U.S. Department of Health and Human Services (HHS), in collaboration with seven pharmaceutical companies and the National Alliance of State and Territorial AIDS Directors  (NASTAD), released an updated Common Patient Assistance Program Application  (CPAPA).  Developed in 2012, the CPAPA is intended to be used by both people living with HIV and their…

Viral Suppression: The Struggle is Real

Recently, I’ve been thinking and talking a lot about the importance of viral suppression. For people living with HIV, getting the virus under control is the most important thing we can do. It’s the key to our own survival, reducing deaths, and preventing new infections. Viral suppression reflects not only the quality of medical care,…